Related Experiment Video

Updated: Aug 23, 2025

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

7.6K

Expression profile of immunoregulatory factors in canine tumors

Kohei Murakami1, Saki Miyatake1, Jiro Miyamae1

  • 1Laboratory of Immunology, Faculty of Veterinary Medicine, Okayama University of Science, Imabari, Ehime 794-8555, Japan.

Veterinary Immunology and Immunopathology
|November 3, 2022
PubMed

Insights

This study maps immune molecules in canine tumors, finding Galectin-9 and CD48 are common. This research aids developing novel immunotherapies for canine cancers, similar to human treatments.

Area of Science:

  • Veterinary Oncology
  • Immunology
  • Molecular Biology

Background:

  • Cancers employ immune evasion strategies.
  • Understanding the tumor immune microenvironment is crucial for developing effective immunotherapies.
  • Canine cancer research can inform human cancer treatment strategies.

Purpose of the Study:

  • To profile the expression of 20 immune regulatory molecules across diverse canine tumors.
  • To identify potential therapeutic targets for canine cancer immunotherapy.

Main Methods:

  • Quantitative RT-PCR (qPCR) was used to screen molecule expression in 59 canine tumors.
  • Immunofluorescence staining confirmed protein expression for specific molecules.

Main Results:

  • Galectin-9 (LGALS9) and CD48 were widely expressed across canine tumors.
  • Programmed Death-Ligand 1 (CD274) and others were rarely expressed.
  • Specific molecules like FGL1, PD-L2, B7x (VTCN1), and CD70 showed distinct expression patterns in certain tumor types (e.g., hepatocellular carcinoma, mast cell tumors, transitional cell carcinomas, lymphomas, squamous cell carcinomas).
  • NECTIN2 and VSIR/CD200 expression varied between epithelial and non-epithelial tumors.

Conclusions:

  • This study provides a comprehensive expression profile of immune regulatory molecules in canine tumors.
  • The findings highlight specific molecules and tumor types that may benefit from targeted immunotherapies.
  • This research advances the understanding of canine anti-tumor immunity and supports the development of novel veterinary cancer treatments.
Keywords:
B7xCD70FGL-1Immune checkpointPD-L2Tumor immunity

More Related Videos

Predictive Immune Modeling of Solid Tumors08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
639
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.3K